Shares of the company are trading at $17.85 just a bit higher than the 50 day moving average which is $16.62 and which is just a bit higher than the 200 day moving average of $16.18. The 50 day moving average was up $1.23 or +7.40% and the 200 day average moved up $1.67. Amphastar Pharmaceuticals, Inc. shares had a trading volume of 208K by the end of trading on Thursday. Overall, volume was down 60.61% under the stocks normal daily volume.
Investors are feeling more bearish on Amphastar Pharmaceuticals, Inc. recently if you pay attention to the change in short interest. The firm recorded a rise in short interest from June 15, 2017 to May 31, 2017 of 17.67%. Short shares increased from 2,761,027 to 3,248,942 over that period. With short interest at 3,248,942 and short average daily volume at 295,099, days to cover is 11.0 and the short interest percentage is 0.07% as of May 31.
Here is the rundown on market activity for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Richard K. Prins, Director reported the sale of 10,000 shares of AMPH stock. The shares were purchased at an average price of $17.07. Prins now owns $492,367 of the stock according to the SEC filing. Michael A. Zasloff, Director disclosed the sale of 15,000 shares of (AMPH). The shares were sold on June 1st for an average price of $17.01. The Director now owns $551,311 of the stock per the Form 4 SEC filing.
President and General Counsel Jason B. Shandell let go of 11,482 shares at a price of $17.01 on Wed the 31st. The President and General Counsel now owns $4,043,073 of the stock as reported to the SEC.
Here are a few other firms who have also updated their positions. Fisher Asset Management, LLC bolstered its investment by buying 44,492 shares an increase of 29.5%. Fisher Asset Management, LLC currently owns 195,547 shares with a value of $3,492,000. The value of the position overall is up by 59.5%. As of quarter end Creative Planning had sold 2,000 shares trimming its position 2.1%. The value of the company’s investment in Amphastar Pharmaceuticals, Inc. increased from $1,391,000 to $1,678,000 increasing 20.6% for the reporting period.
As of the end of the quarter Clinton Group Inc had acquired a total of 17,416 shares growing its stake by 109.6%. The value of the investment in Amphastar Pharmaceuticals, Inc. went from $293,000 to $482,000 a change of $189,000 quarter over quarter. As of the end of the quarter Bank Of Montreal /can/ had disposed of a total of 1,500 shares trimming its holdings by 33.3%. The value of the investment in (AMPH) decreased from $65,000 to $54,000 a change of 16.9% since the last quarter.
BMO Capital initiated coverage on the stock with an initial rating of “Market Perform”. Equity analyst Wells Fargo starting coverage on the stock with a rating of “Outperform”.
On January 19 Jefferies kept the company rating at “Buy” and lowered the price expectation to $17.00 from $18.00. November 13 investment analysts at Jefferies kept the stock rating at “Buy” but raised the price expectation from $18.00 to $19.00.
On June 3, 2015 Raymond James starting coverage on AMPH giving it an initial rating of “Strong Buy” and a price target of $23.00. March 25 investment analysts at Jefferies made no change to the stock rating of “Buy” but raised the price target from $15.00 to $18.00.
The company is trading down since yesterday’s close of $17.86. The company’s P/E ratio is 93.95 and the market cap of the company is 816.41M. As of the last earnings report the EPS was $0.19 and is projected to be $0.40 for the current year with 45,737,000 shares currently outstanding. Next quarter’s EPS is expected be $0.08 with next year’s EPS anticipated to be $0.79.
Amphastar Pharmaceuticals, Inc., launched on May 19, 2004, is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates..